Rifabutin corneal deposits in a patient with acquired immunodeficiency syndrome: in vivo confocal microscopy investigation

Eur J Ophthalmol. 2009 May-Jun;19(3):481-3. doi: 10.1177/112067210901900327.

Abstract

Purpose: To establish the real localization of rifabutin-related corneal deposits in a patient with human immunodeficiency virus (HIV) infection by in vivo HRT II confocal microscopy with related clinicopathologic implications.

Methods: Observational case report. After Siena University Institutional Review Board approval in May 2008 and specific informed consent, a 54-year-old patient with HIV infection under rifabutin treatment for acquired immunodeficiency syndrome-related Mycobacterium avium complex prevention who developed diffuse corneal deposits was examined at the Department of Ophthalmology of Siena University. He underwent a complete clinical eye examination, biomicroscopy, and digital slit lamp photographs, endothelial specular microscopy, ultrasound pachymetry, and confocal microscopy by HRT II system.

Results: Confocal scans revealed the presence of deep stromal and pre descemetic hyperreflective polymorphous deposits. In vivo confocal examination excluded the presence of rifabutin-related deposits at endothelial level.

Conclusions: Confocal microscopy enables establishment of the real localization of rifabutin deposits at deep stromal level, providing a better qualitative analysis of all corneal layers compared to biomicroscopic examination, with clinical and physiopathologic implications.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Anti-HIV Agents / therapeutic use
  • Corneal Diseases / chemically induced*
  • Corneal Diseases / diagnosis
  • Corneal Stroma / drug effects*
  • Corneal Stroma / pathology
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Humans
  • Male
  • Microscopy, Confocal
  • Middle Aged
  • Mycobacterium avium-intracellulare Infection / prevention & control
  • Rifabutin / adverse effects*
  • Rifabutin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Anti-HIV Agents
  • Rifabutin